Ardena Moves to Expanded Headquarters in Belgium

News
Article

Ardena has moved into its expanded headquarters, located in Gent, Belgium, as a result of continued growth.

Ardena, a contract development and manufacturing organization (CDMO), has moved to expanded headquarters in Gent, Belgium, as a result of sustained growth, it has revealed in a Nov. 8, 2018 press release.

Now operating across six sites, located in Belgium, the Netherlands, Sweden, and Latvia, the company has increased its employees from 40 to 250 and seen an increase in organic growth of more than 20% per year, which it states is a result of its merger and acquisition strategy.

"After several acquisitions and an ongoing growth period, we are firmly on track to reach our €35 million (approximately $40 million) sales target for 2018 as part of our wider strategy to become a leading integrated drug development company," said Harry Christiaens, CEO at Ardena in a press statement. "This new, larger headquarters will enable us to free up space for additional laboratories at our other sites and further expand our capabilities. It will also provide a base for our staff training centre to ensure we develop our team. As we move into 2019, we look forward to continued international success and carrying on with our acquisition strategy to further strengthen our service offering."

Inauguration of the new HQ took place on Oct. 25, 2018.

Source: Ardena

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Related Content